11:50:42,408 graphrag.config.read_dotenv INFO Loading pipeline .env file
11:50:42,422 graphrag.index.cli INFO using default configuration: {
    "llm": {
        "api_key": "REDACTED, length 56",
        "type": "openai_chat",
        "model": "llama3-8b-8192",
        "max_tokens": 3000,
        "request_timeout": 300.0,
        "api_base": "https://api.groq.com/openai/v1",
        "api_version": null,
        "proxy": null,
        "cognitive_services_endpoint": null,
        "deployment_name": null,
        "model_supports_json": true,
        "tokens_per_minute": 0,
        "requests_per_minute": 0,
        "max_retries": 5,
        "max_retry_wait": 20.0,
        "sleep_on_rate_limit_recommendation": true,
        "concurrent_requests": 5
    },
    "parallelization": {
        "stagger": 0.5,
        "num_threads": 50
    },
    "async_mode": "threaded",
    "root_dir": ".",
    "reporting": {
        "type": "file",
        "base_dir": "output/${timestamp}/reports",
        "storage_account_blob_url": null
    },
    "storage": {
        "type": "file",
        "base_dir": "output/${timestamp}/artifacts",
        "storage_account_blob_url": null
    },
    "cache": {
        "type": "file",
        "base_dir": "cache",
        "storage_account_blob_url": null
    },
    "input": {
        "type": "file",
        "file_type": "text",
        "base_dir": "input",
        "storage_account_blob_url": null,
        "encoding": "utf-8",
        "file_pattern": ".*\\.txt$",
        "file_filter": null,
        "source_column": null,
        "timestamp_column": null,
        "timestamp_format": null,
        "text_column": "text",
        "title_column": null,
        "document_attribute_columns": []
    },
    "embed_graph": {
        "enabled": false,
        "num_walks": 10,
        "walk_length": 40,
        "window_size": 2,
        "iterations": 3,
        "random_seed": 597832,
        "strategy": null
    },
    "embeddings": {
        "llm": {
            "api_key": "REDACTED, length 56",
            "type": "openai_embedding",
            "model": "nomic-ai/nomic-embed-text-v1.5-GGUF/nomic-embed-text-v1.5.Q2_K.gguf",
            "max_tokens": 4000,
            "request_timeout": 180.0,
            "api_base": "http://localhost:1234/v1",
            "api_version": null,
            "proxy": null,
            "cognitive_services_endpoint": null,
            "deployment_name": null,
            "model_supports_json": null,
            "tokens_per_minute": 0,
            "requests_per_minute": 0,
            "max_retries": 10,
            "max_retry_wait": 20.0,
            "sleep_on_rate_limit_recommendation": true,
            "concurrent_requests": 5
        },
        "parallelization": {
            "stagger": 0.5,
            "num_threads": 50
        },
        "async_mode": "threaded",
        "batch_size": 16,
        "batch_max_tokens": 8191,
        "target": "required",
        "skip": [],
        "vector_store": null,
        "strategy": null
    },
    "chunks": {
        "size": 300,
        "overlap": 100,
        "group_by_columns": [
            "id"
        ],
        "strategy": null
    },
    "snapshots": {
        "graphml": false,
        "raw_entities": false,
        "top_level_nodes": false
    },
    "entity_extraction": {
        "llm": {
            "api_key": "REDACTED, length 56",
            "type": "openai_chat",
            "model": "llama3-8b-8192",
            "max_tokens": 3000,
            "request_timeout": 300.0,
            "api_base": "https://api.groq.com/openai/v1",
            "api_version": null,
            "proxy": null,
            "cognitive_services_endpoint": null,
            "deployment_name": null,
            "model_supports_json": true,
            "tokens_per_minute": 0,
            "requests_per_minute": 0,
            "max_retries": 5,
            "max_retry_wait": 20.0,
            "sleep_on_rate_limit_recommendation": true,
            "concurrent_requests": 5
        },
        "parallelization": {
            "stagger": 0.5,
            "num_threads": 50
        },
        "async_mode": "threaded",
        "prompt": "prompts/entity_extraction.txt",
        "entity_types": [
            "organization",
            "person",
            "geo",
            "event"
        ],
        "max_gleanings": 0,
        "strategy": null
    },
    "summarize_descriptions": {
        "llm": {
            "api_key": "REDACTED, length 56",
            "type": "openai_chat",
            "model": "llama3-8b-8192",
            "max_tokens": 3000,
            "request_timeout": 300.0,
            "api_base": "https://api.groq.com/openai/v1",
            "api_version": null,
            "proxy": null,
            "cognitive_services_endpoint": null,
            "deployment_name": null,
            "model_supports_json": true,
            "tokens_per_minute": 0,
            "requests_per_minute": 0,
            "max_retries": 5,
            "max_retry_wait": 20.0,
            "sleep_on_rate_limit_recommendation": true,
            "concurrent_requests": 5
        },
        "parallelization": {
            "stagger": 0.5,
            "num_threads": 50
        },
        "async_mode": "threaded",
        "prompt": "prompts/summarize_descriptions.txt",
        "max_length": 500,
        "strategy": null
    },
    "community_reports": {
        "llm": {
            "api_key": "REDACTED, length 56",
            "type": "openai_chat",
            "model": "llama3-8b-8192",
            "max_tokens": 3000,
            "request_timeout": 300.0,
            "api_base": "https://api.groq.com/openai/v1",
            "api_version": null,
            "proxy": null,
            "cognitive_services_endpoint": null,
            "deployment_name": null,
            "model_supports_json": true,
            "tokens_per_minute": 0,
            "requests_per_minute": 0,
            "max_retries": 5,
            "max_retry_wait": 20.0,
            "sleep_on_rate_limit_recommendation": true,
            "concurrent_requests": 5
        },
        "parallelization": {
            "stagger": 0.5,
            "num_threads": 50
        },
        "async_mode": "threaded",
        "prompt": null,
        "max_length": 2000,
        "max_input_length": 8000,
        "strategy": null
    },
    "claim_extraction": {
        "llm": {
            "api_key": "REDACTED, length 56",
            "type": "openai_chat",
            "model": "llama3-8b-8192",
            "max_tokens": 3000,
            "request_timeout": 300.0,
            "api_base": "https://api.groq.com/openai/v1",
            "api_version": null,
            "proxy": null,
            "cognitive_services_endpoint": null,
            "deployment_name": null,
            "model_supports_json": true,
            "tokens_per_minute": 0,
            "requests_per_minute": 0,
            "max_retries": 5,
            "max_retry_wait": 20.0,
            "sleep_on_rate_limit_recommendation": true,
            "concurrent_requests": 5
        },
        "parallelization": {
            "stagger": 0.5,
            "num_threads": 50
        },
        "async_mode": "threaded",
        "enabled": false,
        "prompt": "prompts/claim_extraction.txt",
        "description": "Any claims or facts that could be relevant to information discovery.",
        "max_gleanings": 0,
        "strategy": null
    },
    "cluster_graph": {
        "max_cluster_size": 10,
        "strategy": null
    },
    "umap": {
        "enabled": false
    },
    "local_search": {
        "text_unit_prop": 0.5,
        "community_prop": 0.1,
        "conversation_history_max_turns": 5,
        "top_k_entities": 10,
        "top_k_relationships": 10,
        "max_tokens": 12000,
        "llm_max_tokens": 2000
    },
    "global_search": {
        "max_tokens": 3000,
        "data_max_tokens": 12000,
        "map_max_tokens": 1000,
        "reduce_max_tokens": 2000,
        "concurrency": 32
    },
    "encoding_model": "cl100k_base",
    "skip_workflows": []
}
11:50:42,431 graphrag.index.create_pipeline_config INFO skipping workflows 
11:50:42,438 graphrag.index.run INFO Running pipeline
11:50:42,438 graphrag.index.storage.file_pipeline_storage INFO Creating file storage at output\20240715-115042\artifacts
11:50:42,439 graphrag.index.input.load_input INFO loading input from root_dir=input
11:50:42,439 graphrag.index.input.load_input INFO using file storage for input
11:50:42,441 graphrag.index.storage.file_pipeline_storage INFO search input for files matching .*\.txt$
11:50:42,442 graphrag.index.input.text INFO found text files from input, found [('breast_cancer.txt', {})]
11:50:42,455 graphrag.index.workflows.load INFO Workflow Run Order: ['create_base_text_units', 'create_base_extracted_entities', 'create_summarized_entities', 'create_base_entity_graph', 'create_final_entities', 'create_final_nodes', 'create_final_communities', 'join_text_units_to_entity_ids', 'create_final_relationships', 'join_text_units_to_relationship_ids', 'create_final_community_reports', 'create_final_text_units', 'create_base_documents', 'create_final_documents']
11:50:42,455 graphrag.index.run INFO Final # of rows loaded: 1
11:50:42,740 graphrag.index.run INFO Running workflow: create_base_text_units...
11:50:42,740 graphrag.index.run INFO dependencies for create_base_text_units: []
11:50:42,757 datashaper.workflow.workflow INFO executing verb orderby
11:50:42,815 datashaper.workflow.workflow INFO executing verb zip
11:50:42,828 datashaper.workflow.workflow INFO executing verb aggregate_override
11:50:42,855 datashaper.workflow.workflow INFO executing verb chunk
11:50:43,162 datashaper.workflow.workflow INFO executing verb select
11:50:43,169 datashaper.workflow.workflow INFO executing verb unroll
11:50:43,180 datashaper.workflow.workflow INFO executing verb rename
11:50:43,189 datashaper.workflow.workflow INFO executing verb genid
11:50:43,204 datashaper.workflow.workflow INFO executing verb unzip
11:50:43,219 datashaper.workflow.workflow INFO executing verb copy
11:50:43,231 datashaper.workflow.workflow INFO executing verb filter
11:50:43,297 graphrag.index.emit.parquet_table_emitter INFO emitting parquet table create_base_text_units.parquet
11:50:43,732 graphrag.index.run INFO Running workflow: create_base_extracted_entities...
11:50:43,732 graphrag.index.run INFO dependencies for create_base_extracted_entities: ['create_base_text_units']
11:50:43,733 graphrag.index.run INFO read table from storage: create_base_text_units.parquet
11:50:43,847 datashaper.workflow.workflow INFO executing verb entity_extract
11:50:43,876 graphrag.llm.openai.create_openai_client INFO Creating OpenAI client base_url=https://api.groq.com/openai/v1
11:50:43,893 graphrag.index.llm.load_llm INFO create TPM/RPM limiter for llama3-8b-8192: TPM=0, RPM=0
11:50:43,894 graphrag.index.llm.load_llm INFO create concurrency limiter for llama3-8b-8192: 5
11:50:44,284 datashaper.workflow.workflow INFO executing verb merge_graphs
11:50:44,454 graphrag.index.emit.parquet_table_emitter INFO emitting parquet table create_base_extracted_entities.parquet
11:50:44,801 graphrag.index.run INFO Running workflow: create_summarized_entities...
11:50:44,801 graphrag.index.run INFO dependencies for create_summarized_entities: ['create_base_extracted_entities']
11:50:44,802 graphrag.index.run INFO read table from storage: create_base_extracted_entities.parquet
11:50:44,871 datashaper.workflow.workflow INFO executing verb summarize_descriptions
11:50:46,337 graphrag.index.emit.parquet_table_emitter INFO emitting parquet table create_summarized_entities.parquet
11:50:46,702 graphrag.index.run INFO Running workflow: create_base_entity_graph...
11:50:46,716 graphrag.index.run INFO dependencies for create_base_entity_graph: ['create_summarized_entities']
11:50:46,717 graphrag.index.run INFO read table from storage: create_summarized_entities.parquet
11:50:46,776 datashaper.workflow.workflow INFO executing verb cluster_graph
11:50:47,275 datashaper.workflow.workflow INFO executing verb select
11:50:47,282 graphrag.index.emit.parquet_table_emitter INFO emitting parquet table create_base_entity_graph.parquet
11:50:47,604 graphrag.index.run INFO Running workflow: create_final_entities...
11:50:47,604 graphrag.index.run INFO dependencies for create_final_entities: ['create_base_entity_graph']
11:50:47,605 graphrag.index.run INFO read table from storage: create_base_entity_graph.parquet
11:50:47,694 datashaper.workflow.workflow INFO executing verb unpack_graph
11:50:47,928 datashaper.workflow.workflow INFO executing verb rename
11:50:47,941 datashaper.workflow.workflow INFO executing verb select
11:50:47,952 datashaper.workflow.workflow INFO executing verb dedupe
11:50:47,976 datashaper.workflow.workflow INFO executing verb rename
11:50:47,986 datashaper.workflow.workflow INFO executing verb filter
11:50:48,50 datashaper.workflow.workflow INFO executing verb text_split
11:50:48,81 datashaper.workflow.workflow INFO executing verb drop
11:50:48,97 datashaper.workflow.workflow INFO executing verb merge
11:50:48,357 datashaper.workflow.workflow INFO executing verb text_embed
11:50:48,361 graphrag.llm.openai.create_openai_client INFO Creating OpenAI client base_url=http://localhost:1234/v1
11:50:48,373 graphrag.index.llm.load_llm INFO create TPM/RPM limiter for nomic-ai/nomic-embed-text-v1.5-GGUF/nomic-embed-text-v1.5.Q2_K.gguf: TPM=0, RPM=0
11:50:48,373 graphrag.index.llm.load_llm INFO create concurrency limiter for nomic-ai/nomic-embed-text-v1.5-GGUF/nomic-embed-text-v1.5.Q2_K.gguf: 5
11:50:48,496 graphrag.index.verbs.text.embed.strategies.openai INFO embedding 969 inputs via 969 snippets using 61 batches. max_batch_size=16, max_tokens=8191
11:50:51,146 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"HER2+ EARLY BREAST CANCER":"HER2+ early breast cancer is a condition being researched and treated in the NeoALTTO trial."', '"PHER2":"pHER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHER3":"pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER2":"phosphorylated HER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER3":"phosphorylated HER3 is a concept or marker that is associated with response to lapatinib treatment."', '"CO-EXPRESSION":"co-expression of phosphorylated HER2 and pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"DOSE REDUCTION":"dose reduction is an event that may occur due to toxicity of treatment."', '"DISCONTINUATION OF TREATMENT":"discontinuation of treatment is an event that may occur due to toxicity of treatment."', '"TOXICITY":"toxicity is a concept or marker that is associated with the side effects of treatment."', '"RESPONSE RATE":Here is a comprehensive summary of the data:\n\nThe "RESPONSE RATE" refers to the percentage of participants or patients who respond to a treatment. It is a concept or marker that is associated with the effectiveness of treatment. In other words, response rate measures the proportion of individuals who exhibit a positive outcome or improvement in response to a particular treatment or intervention.', '"PREDICTIVE MARKER":"predictive marker is a concept or marker that is associated with the likelihood of response to treatment."', '"PCR RATE":Here is a comprehensive summary of the data:\n\nThe "PCR Rate" is a concept or marker that measures the effectiveness of treatment, specifically in the context of breast cancer and inflammatory breast cancer (IBC). It is an endpoint in clinical trials for IBC and refers to the percentage of patients who achieve a pathologic complete response (pCR) to treatment. In other words, the pCR rate is the rate of patients who achieve a complete response to treatment, as determined by a pathologic examination of the breast tissue. This rate is used to assess the effectiveness of treatments for breast cancer and IBC, providing valuable information for healthcare professionals and researchers.', '"EARLY BREAST CANCER":"early breast cancer is an event or condition being researched and treated."', '"T-DM1":Here is a comprehensive summary of the data:\n\n"T-DM1" is a medication used in the treatment of breast cancer, specifically in the treatment of HER2+ breast cancer. It is a type of antibody-drug conjugate, which is a targeted therapy that combines an antibody with a chemotherapy drug to deliver the treatment directly to the cancer cells. T-DM1 is used to treat HER2+ breast cancer, including HER2+ inflammatory breast cancer (IBC) cases without a pathologic complete response (pCR).', '"KRISTINE TRIAL":Here is a comprehensive summary of the data:\n\nThe KRISTINE trial is a randomized phase 3 trial that evaluated the efficacy of neoadjuvant treatment with T-DM1 plus pertuzumab in patients with HER2+ breast cancer. Specifically, the trial aimed to assess the effectiveness of this combination therapy in treating HER2+ breast cancer.\n\nNote: I resolved the contradiction by combining the two descriptions to provide a single, coherent summary.', '"TCHP REGIMEN":Here is a comprehensive summary of the data:\n\nThe "TCHP REGIMEN" is a chemotherapy regimen used to treat breast cancer. Specifically, it is a combination therapy that includes trastuzumab and pertuzumab, two targeted therapies that work together to combat the disease.']}
11:50:51,150 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"ZAKS T":Here is a comprehensive summary of the data:\n\nZaks T is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.', '"DESILVIO M":Here is a comprehensive summary of the data:\n\nDeSilvio M is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.', '"SALAZAR V":Here is a comprehensive summary of the data:\n\nSalazar V is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.', '"SPECTOR N":Here is a comprehensive summary of the data:\n\nSPECTOR N is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.', '"G5":"G5 is a study evaluating the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer."', '"ALVAREZ RH":Here is a comprehensive summary of the data:\n\nALVAREZ RH is an author of research papers on inflammatory breast cancer. Specifically, Alvarez RH is an author of a study on the limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients.', '"ENSOR J":"Ensor J is an author of a study on limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients."', '"HUONG TLP":"Huong TLP is an author of a study on limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients."', '"JOHNSTON S":"Johnston S is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"TRUDEAU M":"Trudeau M is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"KAUFMAN B":"Kaufman B is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"BLACKWELL K":"Blackwell K is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"LORUSSO P":"LoRusso P is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"J CLIN ONCOL CONF":"J Clin Oncol Conf is a conference that presented a study on limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients."', '"PHASE II STUDY":"Phase II study is a type of clinical trial that evaluated the efficacy and safety of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients.""Phase II study is a type of clinical trial that evaluated the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer."', '"PREDICTIVE BIOMARKER PROFILES":"Predictive biomarker profiles refer to the identification of biomarkers that can predict response to treatment targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."']}
11:50:54,519 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"ZAKS T":Here is a comprehensive summary of the data:\n\nZaks T is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.', '"DESILVIO M":Here is a comprehensive summary of the data:\n\nDeSilvio M is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.', '"SALAZAR V":Here is a comprehensive summary of the data:\n\nSalazar V is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.', '"SPECTOR N":Here is a comprehensive summary of the data:\n\nSPECTOR N is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.', '"G5":"G5 is a study evaluating the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer."', '"ALVAREZ RH":Here is a comprehensive summary of the data:\n\nALVAREZ RH is an author of research papers on inflammatory breast cancer. Specifically, Alvarez RH is an author of a study on the limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients.', '"ENSOR J":"Ensor J is an author of a study on limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients."', '"HUONG TLP":"Huong TLP is an author of a study on limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients."', '"JOHNSTON S":"Johnston S is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"TRUDEAU M":"Trudeau M is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"KAUFMAN B":"Kaufman B is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"BLACKWELL K":"Blackwell K is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"LORUSSO P":"LoRusso P is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"J CLIN ONCOL CONF":"J Clin Oncol Conf is a conference that presented a study on limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients."', '"PHASE II STUDY":"Phase II study is a type of clinical trial that evaluated the efficacy and safety of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients.""Phase II study is a type of clinical trial that evaluated the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer."', '"PREDICTIVE BIOMARKER PROFILES":"Predictive biomarker profiles refer to the identification of biomarkers that can predict response to treatment targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."']}
11:50:54,627 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"HER2+ EARLY BREAST CANCER":"HER2+ early breast cancer is a condition being researched and treated in the NeoALTTO trial."', '"PHER2":"pHER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHER3":"pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER2":"phosphorylated HER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER3":"phosphorylated HER3 is a concept or marker that is associated with response to lapatinib treatment."', '"CO-EXPRESSION":"co-expression of phosphorylated HER2 and pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"DOSE REDUCTION":"dose reduction is an event that may occur due to toxicity of treatment."', '"DISCONTINUATION OF TREATMENT":"discontinuation of treatment is an event that may occur due to toxicity of treatment."', '"TOXICITY":"toxicity is a concept or marker that is associated with the side effects of treatment."', '"RESPONSE RATE":Here is a comprehensive summary of the data:\n\nThe "RESPONSE RATE" refers to the percentage of participants or patients who respond to a treatment. It is a concept or marker that is associated with the effectiveness of treatment. In other words, response rate measures the proportion of individuals who exhibit a positive outcome or improvement in response to a particular treatment or intervention.', '"PREDICTIVE MARKER":"predictive marker is a concept or marker that is associated with the likelihood of response to treatment."', '"PCR RATE":Here is a comprehensive summary of the data:\n\nThe "PCR Rate" is a concept or marker that measures the effectiveness of treatment, specifically in the context of breast cancer and inflammatory breast cancer (IBC). It is an endpoint in clinical trials for IBC and refers to the percentage of patients who achieve a pathologic complete response (pCR) to treatment. In other words, the pCR rate is the rate of patients who achieve a complete response to treatment, as determined by a pathologic examination of the breast tissue. This rate is used to assess the effectiveness of treatments for breast cancer and IBC, providing valuable information for healthcare professionals and researchers.', '"EARLY BREAST CANCER":"early breast cancer is an event or condition being researched and treated."', '"T-DM1":Here is a comprehensive summary of the data:\n\n"T-DM1" is a medication used in the treatment of breast cancer, specifically in the treatment of HER2+ breast cancer. It is a type of antibody-drug conjugate, which is a targeted therapy that combines an antibody with a chemotherapy drug to deliver the treatment directly to the cancer cells. T-DM1 is used to treat HER2+ breast cancer, including HER2+ inflammatory breast cancer (IBC) cases without a pathologic complete response (pCR).', '"KRISTINE TRIAL":Here is a comprehensive summary of the data:\n\nThe KRISTINE trial is a randomized phase 3 trial that evaluated the efficacy of neoadjuvant treatment with T-DM1 plus pertuzumab in patients with HER2+ breast cancer. Specifically, the trial aimed to assess the effectiveness of this combination therapy in treating HER2+ breast cancer.\n\nNote: I resolved the contradiction by combining the two descriptions to provide a single, coherent summary.', '"TCHP REGIMEN":Here is a comprehensive summary of the data:\n\nThe "TCHP REGIMEN" is a chemotherapy regimen used to treat breast cancer. Specifically, it is a combination therapy that includes trastuzumab and pertuzumab, two targeted therapies that work together to combat the disease.']}
11:50:59,64 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"ZAKS T":Here is a comprehensive summary of the data:\n\nZaks T is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.', '"DESILVIO M":Here is a comprehensive summary of the data:\n\nDeSilvio M is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.', '"SALAZAR V":Here is a comprehensive summary of the data:\n\nSalazar V is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.', '"SPECTOR N":Here is a comprehensive summary of the data:\n\nSPECTOR N is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.', '"G5":"G5 is a study evaluating the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer."', '"ALVAREZ RH":Here is a comprehensive summary of the data:\n\nALVAREZ RH is an author of research papers on inflammatory breast cancer. Specifically, Alvarez RH is an author of a study on the limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients.', '"ENSOR J":"Ensor J is an author of a study on limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients."', '"HUONG TLP":"Huong TLP is an author of a study on limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients."', '"JOHNSTON S":"Johnston S is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"TRUDEAU M":"Trudeau M is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"KAUFMAN B":"Kaufman B is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"BLACKWELL K":"Blackwell K is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"LORUSSO P":"LoRusso P is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"J CLIN ONCOL CONF":"J Clin Oncol Conf is a conference that presented a study on limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients."', '"PHASE II STUDY":"Phase II study is a type of clinical trial that evaluated the efficacy and safety of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients.""Phase II study is a type of clinical trial that evaluated the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer."', '"PREDICTIVE BIOMARKER PROFILES":"Predictive biomarker profiles refer to the identification of biomarkers that can predict response to treatment targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."']}
11:50:59,437 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"HER2+ EARLY BREAST CANCER":"HER2+ early breast cancer is a condition being researched and treated in the NeoALTTO trial."', '"PHER2":"pHER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHER3":"pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER2":"phosphorylated HER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER3":"phosphorylated HER3 is a concept or marker that is associated with response to lapatinib treatment."', '"CO-EXPRESSION":"co-expression of phosphorylated HER2 and pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"DOSE REDUCTION":"dose reduction is an event that may occur due to toxicity of treatment."', '"DISCONTINUATION OF TREATMENT":"discontinuation of treatment is an event that may occur due to toxicity of treatment."', '"TOXICITY":"toxicity is a concept or marker that is associated with the side effects of treatment."', '"RESPONSE RATE":Here is a comprehensive summary of the data:\n\nThe "RESPONSE RATE" refers to the percentage of participants or patients who respond to a treatment. It is a concept or marker that is associated with the effectiveness of treatment. In other words, response rate measures the proportion of individuals who exhibit a positive outcome or improvement in response to a particular treatment or intervention.', '"PREDICTIVE MARKER":"predictive marker is a concept or marker that is associated with the likelihood of response to treatment."', '"PCR RATE":Here is a comprehensive summary of the data:\n\nThe "PCR Rate" is a concept or marker that measures the effectiveness of treatment, specifically in the context of breast cancer and inflammatory breast cancer (IBC). It is an endpoint in clinical trials for IBC and refers to the percentage of patients who achieve a pathologic complete response (pCR) to treatment. In other words, the pCR rate is the rate of patients who achieve a complete response to treatment, as determined by a pathologic examination of the breast tissue. This rate is used to assess the effectiveness of treatments for breast cancer and IBC, providing valuable information for healthcare professionals and researchers.', '"EARLY BREAST CANCER":"early breast cancer is an event or condition being researched and treated."', '"T-DM1":Here is a comprehensive summary of the data:\n\n"T-DM1" is a medication used in the treatment of breast cancer, specifically in the treatment of HER2+ breast cancer. It is a type of antibody-drug conjugate, which is a targeted therapy that combines an antibody with a chemotherapy drug to deliver the treatment directly to the cancer cells. T-DM1 is used to treat HER2+ breast cancer, including HER2+ inflammatory breast cancer (IBC) cases without a pathologic complete response (pCR).', '"KRISTINE TRIAL":Here is a comprehensive summary of the data:\n\nThe KRISTINE trial is a randomized phase 3 trial that evaluated the efficacy of neoadjuvant treatment with T-DM1 plus pertuzumab in patients with HER2+ breast cancer. Specifically, the trial aimed to assess the effectiveness of this combination therapy in treating HER2+ breast cancer.\n\nNote: I resolved the contradiction by combining the two descriptions to provide a single, coherent summary.', '"TCHP REGIMEN":Here is a comprehensive summary of the data:\n\nThe "TCHP REGIMEN" is a chemotherapy regimen used to treat breast cancer. Specifically, it is a combination therapy that includes trastuzumab and pertuzumab, two targeted therapies that work together to combat the disease.']}
11:51:06,57 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"ZAKS T":Here is a comprehensive summary of the data:\n\nZaks T is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.', '"DESILVIO M":Here is a comprehensive summary of the data:\n\nDeSilvio M is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.', '"SALAZAR V":Here is a comprehensive summary of the data:\n\nSalazar V is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.', '"SPECTOR N":Here is a comprehensive summary of the data:\n\nSPECTOR N is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.', '"G5":"G5 is a study evaluating the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer."', '"ALVAREZ RH":Here is a comprehensive summary of the data:\n\nALVAREZ RH is an author of research papers on inflammatory breast cancer. Specifically, Alvarez RH is an author of a study on the limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients.', '"ENSOR J":"Ensor J is an author of a study on limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients."', '"HUONG TLP":"Huong TLP is an author of a study on limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients."', '"JOHNSTON S":"Johnston S is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"TRUDEAU M":"Trudeau M is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"KAUFMAN B":"Kaufman B is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"BLACKWELL K":"Blackwell K is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"LORUSSO P":"LoRusso P is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"J CLIN ONCOL CONF":"J Clin Oncol Conf is a conference that presented a study on limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients."', '"PHASE II STUDY":"Phase II study is a type of clinical trial that evaluated the efficacy and safety of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients.""Phase II study is a type of clinical trial that evaluated the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer."', '"PREDICTIVE BIOMARKER PROFILES":"Predictive biomarker profiles refer to the identification of biomarkers that can predict response to treatment targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."']}
11:51:06,510 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"HER2+ EARLY BREAST CANCER":"HER2+ early breast cancer is a condition being researched and treated in the NeoALTTO trial."', '"PHER2":"pHER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHER3":"pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER2":"phosphorylated HER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER3":"phosphorylated HER3 is a concept or marker that is associated with response to lapatinib treatment."', '"CO-EXPRESSION":"co-expression of phosphorylated HER2 and pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"DOSE REDUCTION":"dose reduction is an event that may occur due to toxicity of treatment."', '"DISCONTINUATION OF TREATMENT":"discontinuation of treatment is an event that may occur due to toxicity of treatment."', '"TOXICITY":"toxicity is a concept or marker that is associated with the side effects of treatment."', '"RESPONSE RATE":Here is a comprehensive summary of the data:\n\nThe "RESPONSE RATE" refers to the percentage of participants or patients who respond to a treatment. It is a concept or marker that is associated with the effectiveness of treatment. In other words, response rate measures the proportion of individuals who exhibit a positive outcome or improvement in response to a particular treatment or intervention.', '"PREDICTIVE MARKER":"predictive marker is a concept or marker that is associated with the likelihood of response to treatment."', '"PCR RATE":Here is a comprehensive summary of the data:\n\nThe "PCR Rate" is a concept or marker that measures the effectiveness of treatment, specifically in the context of breast cancer and inflammatory breast cancer (IBC). It is an endpoint in clinical trials for IBC and refers to the percentage of patients who achieve a pathologic complete response (pCR) to treatment. In other words, the pCR rate is the rate of patients who achieve a complete response to treatment, as determined by a pathologic examination of the breast tissue. This rate is used to assess the effectiveness of treatments for breast cancer and IBC, providing valuable information for healthcare professionals and researchers.', '"EARLY BREAST CANCER":"early breast cancer is an event or condition being researched and treated."', '"T-DM1":Here is a comprehensive summary of the data:\n\n"T-DM1" is a medication used in the treatment of breast cancer, specifically in the treatment of HER2+ breast cancer. It is a type of antibody-drug conjugate, which is a targeted therapy that combines an antibody with a chemotherapy drug to deliver the treatment directly to the cancer cells. T-DM1 is used to treat HER2+ breast cancer, including HER2+ inflammatory breast cancer (IBC) cases without a pathologic complete response (pCR).', '"KRISTINE TRIAL":Here is a comprehensive summary of the data:\n\nThe KRISTINE trial is a randomized phase 3 trial that evaluated the efficacy of neoadjuvant treatment with T-DM1 plus pertuzumab in patients with HER2+ breast cancer. Specifically, the trial aimed to assess the effectiveness of this combination therapy in treating HER2+ breast cancer.\n\nNote: I resolved the contradiction by combining the two descriptions to provide a single, coherent summary.', '"TCHP REGIMEN":Here is a comprehensive summary of the data:\n\nThe "TCHP REGIMEN" is a chemotherapy regimen used to treat breast cancer. Specifically, it is a combination therapy that includes trastuzumab and pertuzumab, two targeted therapies that work together to combat the disease.']}
11:51:16,689 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"ZAKS T":Here is a comprehensive summary of the data:\n\nZaks T is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.', '"DESILVIO M":Here is a comprehensive summary of the data:\n\nDeSilvio M is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.', '"SALAZAR V":Here is a comprehensive summary of the data:\n\nSalazar V is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.', '"SPECTOR N":Here is a comprehensive summary of the data:\n\nSPECTOR N is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.', '"G5":"G5 is a study evaluating the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer."', '"ALVAREZ RH":Here is a comprehensive summary of the data:\n\nALVAREZ RH is an author of research papers on inflammatory breast cancer. Specifically, Alvarez RH is an author of a study on the limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients.', '"ENSOR J":"Ensor J is an author of a study on limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients."', '"HUONG TLP":"Huong TLP is an author of a study on limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients."', '"JOHNSTON S":"Johnston S is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"TRUDEAU M":"Trudeau M is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"KAUFMAN B":"Kaufman B is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"BLACKWELL K":"Blackwell K is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"LORUSSO P":"LoRusso P is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"J CLIN ONCOL CONF":"J Clin Oncol Conf is a conference that presented a study on limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients."', '"PHASE II STUDY":"Phase II study is a type of clinical trial that evaluated the efficacy and safety of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients.""Phase II study is a type of clinical trial that evaluated the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer."', '"PREDICTIVE BIOMARKER PROFILES":"Predictive biomarker profiles refer to the identification of biomarkers that can predict response to treatment targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."']}
11:51:16,984 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"HER2+ EARLY BREAST CANCER":"HER2+ early breast cancer is a condition being researched and treated in the NeoALTTO trial."', '"PHER2":"pHER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHER3":"pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER2":"phosphorylated HER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER3":"phosphorylated HER3 is a concept or marker that is associated with response to lapatinib treatment."', '"CO-EXPRESSION":"co-expression of phosphorylated HER2 and pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"DOSE REDUCTION":"dose reduction is an event that may occur due to toxicity of treatment."', '"DISCONTINUATION OF TREATMENT":"discontinuation of treatment is an event that may occur due to toxicity of treatment."', '"TOXICITY":"toxicity is a concept or marker that is associated with the side effects of treatment."', '"RESPONSE RATE":Here is a comprehensive summary of the data:\n\nThe "RESPONSE RATE" refers to the percentage of participants or patients who respond to a treatment. It is a concept or marker that is associated with the effectiveness of treatment. In other words, response rate measures the proportion of individuals who exhibit a positive outcome or improvement in response to a particular treatment or intervention.', '"PREDICTIVE MARKER":"predictive marker is a concept or marker that is associated with the likelihood of response to treatment."', '"PCR RATE":Here is a comprehensive summary of the data:\n\nThe "PCR Rate" is a concept or marker that measures the effectiveness of treatment, specifically in the context of breast cancer and inflammatory breast cancer (IBC). It is an endpoint in clinical trials for IBC and refers to the percentage of patients who achieve a pathologic complete response (pCR) to treatment. In other words, the pCR rate is the rate of patients who achieve a complete response to treatment, as determined by a pathologic examination of the breast tissue. This rate is used to assess the effectiveness of treatments for breast cancer and IBC, providing valuable information for healthcare professionals and researchers.', '"EARLY BREAST CANCER":"early breast cancer is an event or condition being researched and treated."', '"T-DM1":Here is a comprehensive summary of the data:\n\n"T-DM1" is a medication used in the treatment of breast cancer, specifically in the treatment of HER2+ breast cancer. It is a type of antibody-drug conjugate, which is a targeted therapy that combines an antibody with a chemotherapy drug to deliver the treatment directly to the cancer cells. T-DM1 is used to treat HER2+ breast cancer, including HER2+ inflammatory breast cancer (IBC) cases without a pathologic complete response (pCR).', '"KRISTINE TRIAL":Here is a comprehensive summary of the data:\n\nThe KRISTINE trial is a randomized phase 3 trial that evaluated the efficacy of neoadjuvant treatment with T-DM1 plus pertuzumab in patients with HER2+ breast cancer. Specifically, the trial aimed to assess the effectiveness of this combination therapy in treating HER2+ breast cancer.\n\nNote: I resolved the contradiction by combining the two descriptions to provide a single, coherent summary.', '"TCHP REGIMEN":Here is a comprehensive summary of the data:\n\nThe "TCHP REGIMEN" is a chemotherapy regimen used to treat breast cancer. Specifically, it is a combination therapy that includes trastuzumab and pertuzumab, two targeted therapies that work together to combat the disease.']}
11:51:35,694 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"HER2+ EARLY BREAST CANCER":"HER2+ early breast cancer is a condition being researched and treated in the NeoALTTO trial."', '"PHER2":"pHER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHER3":"pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER2":"phosphorylated HER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER3":"phosphorylated HER3 is a concept or marker that is associated with response to lapatinib treatment."', '"CO-EXPRESSION":"co-expression of phosphorylated HER2 and pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"DOSE REDUCTION":"dose reduction is an event that may occur due to toxicity of treatment."', '"DISCONTINUATION OF TREATMENT":"discontinuation of treatment is an event that may occur due to toxicity of treatment."', '"TOXICITY":"toxicity is a concept or marker that is associated with the side effects of treatment."', '"RESPONSE RATE":Here is a comprehensive summary of the data:\n\nThe "RESPONSE RATE" refers to the percentage of participants or patients who respond to a treatment. It is a concept or marker that is associated with the effectiveness of treatment. In other words, response rate measures the proportion of individuals who exhibit a positive outcome or improvement in response to a particular treatment or intervention.', '"PREDICTIVE MARKER":"predictive marker is a concept or marker that is associated with the likelihood of response to treatment."', '"PCR RATE":Here is a comprehensive summary of the data:\n\nThe "PCR Rate" is a concept or marker that measures the effectiveness of treatment, specifically in the context of breast cancer and inflammatory breast cancer (IBC). It is an endpoint in clinical trials for IBC and refers to the percentage of patients who achieve a pathologic complete response (pCR) to treatment. In other words, the pCR rate is the rate of patients who achieve a complete response to treatment, as determined by a pathologic examination of the breast tissue. This rate is used to assess the effectiveness of treatments for breast cancer and IBC, providing valuable information for healthcare professionals and researchers.', '"EARLY BREAST CANCER":"early breast cancer is an event or condition being researched and treated."', '"T-DM1":Here is a comprehensive summary of the data:\n\n"T-DM1" is a medication used in the treatment of breast cancer, specifically in the treatment of HER2+ breast cancer. It is a type of antibody-drug conjugate, which is a targeted therapy that combines an antibody with a chemotherapy drug to deliver the treatment directly to the cancer cells. T-DM1 is used to treat HER2+ breast cancer, including HER2+ inflammatory breast cancer (IBC) cases without a pathologic complete response (pCR).', '"KRISTINE TRIAL":Here is a comprehensive summary of the data:\n\nThe KRISTINE trial is a randomized phase 3 trial that evaluated the efficacy of neoadjuvant treatment with T-DM1 plus pertuzumab in patients with HER2+ breast cancer. Specifically, the trial aimed to assess the effectiveness of this combination therapy in treating HER2+ breast cancer.\n\nNote: I resolved the contradiction by combining the two descriptions to provide a single, coherent summary.', '"TCHP REGIMEN":Here is a comprehensive summary of the data:\n\nThe "TCHP REGIMEN" is a chemotherapy regimen used to treat breast cancer. Specifically, it is a combination therapy that includes trastuzumab and pertuzumab, two targeted therapies that work together to combat the disease.']}
11:51:35,975 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"ZAKS T":Here is a comprehensive summary of the data:\n\nZaks T is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.', '"DESILVIO M":Here is a comprehensive summary of the data:\n\nDeSilvio M is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.', '"SALAZAR V":Here is a comprehensive summary of the data:\n\nSalazar V is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.', '"SPECTOR N":Here is a comprehensive summary of the data:\n\nSPECTOR N is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.', '"G5":"G5 is a study evaluating the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer."', '"ALVAREZ RH":Here is a comprehensive summary of the data:\n\nALVAREZ RH is an author of research papers on inflammatory breast cancer. Specifically, Alvarez RH is an author of a study on the limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients.', '"ENSOR J":"Ensor J is an author of a study on limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients."', '"HUONG TLP":"Huong TLP is an author of a study on limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients."', '"JOHNSTON S":"Johnston S is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"TRUDEAU M":"Trudeau M is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"KAUFMAN B":"Kaufman B is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"BLACKWELL K":"Blackwell K is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"LORUSSO P":"LoRusso P is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"J CLIN ONCOL CONF":"J Clin Oncol Conf is a conference that presented a study on limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients."', '"PHASE II STUDY":"Phase II study is a type of clinical trial that evaluated the efficacy and safety of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients.""Phase II study is a type of clinical trial that evaluated the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer."', '"PREDICTIVE BIOMARKER PROFILES":"Predictive biomarker profiles refer to the identification of biomarkers that can predict response to treatment targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."']}
11:51:58,20 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"HER2+ EARLY BREAST CANCER":"HER2+ early breast cancer is a condition being researched and treated in the NeoALTTO trial."', '"PHER2":"pHER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHER3":"pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER2":"phosphorylated HER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER3":"phosphorylated HER3 is a concept or marker that is associated with response to lapatinib treatment."', '"CO-EXPRESSION":"co-expression of phosphorylated HER2 and pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"DOSE REDUCTION":"dose reduction is an event that may occur due to toxicity of treatment."', '"DISCONTINUATION OF TREATMENT":"discontinuation of treatment is an event that may occur due to toxicity of treatment."', '"TOXICITY":"toxicity is a concept or marker that is associated with the side effects of treatment."', '"RESPONSE RATE":Here is a comprehensive summary of the data:\n\nThe "RESPONSE RATE" refers to the percentage of participants or patients who respond to a treatment. It is a concept or marker that is associated with the effectiveness of treatment. In other words, response rate measures the proportion of individuals who exhibit a positive outcome or improvement in response to a particular treatment or intervention.', '"PREDICTIVE MARKER":"predictive marker is a concept or marker that is associated with the likelihood of response to treatment."', '"PCR RATE":Here is a comprehensive summary of the data:\n\nThe "PCR Rate" is a concept or marker that measures the effectiveness of treatment, specifically in the context of breast cancer and inflammatory breast cancer (IBC). It is an endpoint in clinical trials for IBC and refers to the percentage of patients who achieve a pathologic complete response (pCR) to treatment. In other words, the pCR rate is the rate of patients who achieve a complete response to treatment, as determined by a pathologic examination of the breast tissue. This rate is used to assess the effectiveness of treatments for breast cancer and IBC, providing valuable information for healthcare professionals and researchers.', '"EARLY BREAST CANCER":"early breast cancer is an event or condition being researched and treated."', '"T-DM1":Here is a comprehensive summary of the data:\n\n"T-DM1" is a medication used in the treatment of breast cancer, specifically in the treatment of HER2+ breast cancer. It is a type of antibody-drug conjugate, which is a targeted therapy that combines an antibody with a chemotherapy drug to deliver the treatment directly to the cancer cells. T-DM1 is used to treat HER2+ breast cancer, including HER2+ inflammatory breast cancer (IBC) cases without a pathologic complete response (pCR).', '"KRISTINE TRIAL":Here is a comprehensive summary of the data:\n\nThe KRISTINE trial is a randomized phase 3 trial that evaluated the efficacy of neoadjuvant treatment with T-DM1 plus pertuzumab in patients with HER2+ breast cancer. Specifically, the trial aimed to assess the effectiveness of this combination therapy in treating HER2+ breast cancer.\n\nNote: I resolved the contradiction by combining the two descriptions to provide a single, coherent summary.', '"TCHP REGIMEN":Here is a comprehensive summary of the data:\n\nThe "TCHP REGIMEN" is a chemotherapy regimen used to treat breast cancer. Specifically, it is a combination therapy that includes trastuzumab and pertuzumab, two targeted therapies that work together to combat the disease.']}
11:51:58,316 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"ZAKS T":Here is a comprehensive summary of the data:\n\nZaks T is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.', '"DESILVIO M":Here is a comprehensive summary of the data:\n\nDeSilvio M is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.', '"SALAZAR V":Here is a comprehensive summary of the data:\n\nSalazar V is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.', '"SPECTOR N":Here is a comprehensive summary of the data:\n\nSPECTOR N is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.', '"G5":"G5 is a study evaluating the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer."', '"ALVAREZ RH":Here is a comprehensive summary of the data:\n\nALVAREZ RH is an author of research papers on inflammatory breast cancer. Specifically, Alvarez RH is an author of a study on the limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients.', '"ENSOR J":"Ensor J is an author of a study on limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients."', '"HUONG TLP":"Huong TLP is an author of a study on limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients."', '"JOHNSTON S":"Johnston S is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"TRUDEAU M":"Trudeau M is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"KAUFMAN B":"Kaufman B is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"BLACKWELL K":"Blackwell K is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"LORUSSO P":"LoRusso P is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"J CLIN ONCOL CONF":"J Clin Oncol Conf is a conference that presented a study on limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients."', '"PHASE II STUDY":"Phase II study is a type of clinical trial that evaluated the efficacy and safety of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients.""Phase II study is a type of clinical trial that evaluated the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer."', '"PREDICTIVE BIOMARKER PROFILES":"Predictive biomarker profiles refer to the identification of biomarkers that can predict response to treatment targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."']}
11:52:20,350 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"HER2+ EARLY BREAST CANCER":"HER2+ early breast cancer is a condition being researched and treated in the NeoALTTO trial."', '"PHER2":"pHER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHER3":"pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER2":"phosphorylated HER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER3":"phosphorylated HER3 is a concept or marker that is associated with response to lapatinib treatment."', '"CO-EXPRESSION":"co-expression of phosphorylated HER2 and pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"DOSE REDUCTION":"dose reduction is an event that may occur due to toxicity of treatment."', '"DISCONTINUATION OF TREATMENT":"discontinuation of treatment is an event that may occur due to toxicity of treatment."', '"TOXICITY":"toxicity is a concept or marker that is associated with the side effects of treatment."', '"RESPONSE RATE":Here is a comprehensive summary of the data:\n\nThe "RESPONSE RATE" refers to the percentage of participants or patients who respond to a treatment. It is a concept or marker that is associated with the effectiveness of treatment. In other words, response rate measures the proportion of individuals who exhibit a positive outcome or improvement in response to a particular treatment or intervention.', '"PREDICTIVE MARKER":"predictive marker is a concept or marker that is associated with the likelihood of response to treatment."', '"PCR RATE":Here is a comprehensive summary of the data:\n\nThe "PCR Rate" is a concept or marker that measures the effectiveness of treatment, specifically in the context of breast cancer and inflammatory breast cancer (IBC). It is an endpoint in clinical trials for IBC and refers to the percentage of patients who achieve a pathologic complete response (pCR) to treatment. In other words, the pCR rate is the rate of patients who achieve a complete response to treatment, as determined by a pathologic examination of the breast tissue. This rate is used to assess the effectiveness of treatments for breast cancer and IBC, providing valuable information for healthcare professionals and researchers.', '"EARLY BREAST CANCER":"early breast cancer is an event or condition being researched and treated."', '"T-DM1":Here is a comprehensive summary of the data:\n\n"T-DM1" is a medication used in the treatment of breast cancer, specifically in the treatment of HER2+ breast cancer. It is a type of antibody-drug conjugate, which is a targeted therapy that combines an antibody with a chemotherapy drug to deliver the treatment directly to the cancer cells. T-DM1 is used to treat HER2+ breast cancer, including HER2+ inflammatory breast cancer (IBC) cases without a pathologic complete response (pCR).', '"KRISTINE TRIAL":Here is a comprehensive summary of the data:\n\nThe KRISTINE trial is a randomized phase 3 trial that evaluated the efficacy of neoadjuvant treatment with T-DM1 plus pertuzumab in patients with HER2+ breast cancer. Specifically, the trial aimed to assess the effectiveness of this combination therapy in treating HER2+ breast cancer.\n\nNote: I resolved the contradiction by combining the two descriptions to provide a single, coherent summary.', '"TCHP REGIMEN":Here is a comprehensive summary of the data:\n\nThe "TCHP REGIMEN" is a chemotherapy regimen used to treat breast cancer. Specifically, it is a combination therapy that includes trastuzumab and pertuzumab, two targeted therapies that work together to combat the disease.']}
11:52:20,661 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"ZAKS T":Here is a comprehensive summary of the data:\n\nZaks T is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.', '"DESILVIO M":Here is a comprehensive summary of the data:\n\nDeSilvio M is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.', '"SALAZAR V":Here is a comprehensive summary of the data:\n\nSalazar V is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.', '"SPECTOR N":Here is a comprehensive summary of the data:\n\nSPECTOR N is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.', '"G5":"G5 is a study evaluating the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer."', '"ALVAREZ RH":Here is a comprehensive summary of the data:\n\nALVAREZ RH is an author of research papers on inflammatory breast cancer. Specifically, Alvarez RH is an author of a study on the limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients.', '"ENSOR J":"Ensor J is an author of a study on limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients."', '"HUONG TLP":"Huong TLP is an author of a study on limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients."', '"JOHNSTON S":"Johnston S is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"TRUDEAU M":"Trudeau M is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"KAUFMAN B":"Kaufman B is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"BLACKWELL K":"Blackwell K is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"LORUSSO P":"LoRusso P is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"J CLIN ONCOL CONF":"J Clin Oncol Conf is a conference that presented a study on limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients."', '"PHASE II STUDY":"Phase II study is a type of clinical trial that evaluated the efficacy and safety of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients.""Phase II study is a type of clinical trial that evaluated the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer."', '"PREDICTIVE BIOMARKER PROFILES":"Predictive biomarker profiles refer to the identification of biomarkers that can predict response to treatment targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."']}
11:52:42,661 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"HER2+ EARLY BREAST CANCER":"HER2+ early breast cancer is a condition being researched and treated in the NeoALTTO trial."', '"PHER2":"pHER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHER3":"pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER2":"phosphorylated HER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER3":"phosphorylated HER3 is a concept or marker that is associated with response to lapatinib treatment."', '"CO-EXPRESSION":"co-expression of phosphorylated HER2 and pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"DOSE REDUCTION":"dose reduction is an event that may occur due to toxicity of treatment."', '"DISCONTINUATION OF TREATMENT":"discontinuation of treatment is an event that may occur due to toxicity of treatment."', '"TOXICITY":"toxicity is a concept or marker that is associated with the side effects of treatment."', '"RESPONSE RATE":Here is a comprehensive summary of the data:\n\nThe "RESPONSE RATE" refers to the percentage of participants or patients who respond to a treatment. It is a concept or marker that is associated with the effectiveness of treatment. In other words, response rate measures the proportion of individuals who exhibit a positive outcome or improvement in response to a particular treatment or intervention.', '"PREDICTIVE MARKER":"predictive marker is a concept or marker that is associated with the likelihood of response to treatment."', '"PCR RATE":Here is a comprehensive summary of the data:\n\nThe "PCR Rate" is a concept or marker that measures the effectiveness of treatment, specifically in the context of breast cancer and inflammatory breast cancer (IBC). It is an endpoint in clinical trials for IBC and refers to the percentage of patients who achieve a pathologic complete response (pCR) to treatment. In other words, the pCR rate is the rate of patients who achieve a complete response to treatment, as determined by a pathologic examination of the breast tissue. This rate is used to assess the effectiveness of treatments for breast cancer and IBC, providing valuable information for healthcare professionals and researchers.', '"EARLY BREAST CANCER":"early breast cancer is an event or condition being researched and treated."', '"T-DM1":Here is a comprehensive summary of the data:\n\n"T-DM1" is a medication used in the treatment of breast cancer, specifically in the treatment of HER2+ breast cancer. It is a type of antibody-drug conjugate, which is a targeted therapy that combines an antibody with a chemotherapy drug to deliver the treatment directly to the cancer cells. T-DM1 is used to treat HER2+ breast cancer, including HER2+ inflammatory breast cancer (IBC) cases without a pathologic complete response (pCR).', '"KRISTINE TRIAL":Here is a comprehensive summary of the data:\n\nThe KRISTINE trial is a randomized phase 3 trial that evaluated the efficacy of neoadjuvant treatment with T-DM1 plus pertuzumab in patients with HER2+ breast cancer. Specifically, the trial aimed to assess the effectiveness of this combination therapy in treating HER2+ breast cancer.\n\nNote: I resolved the contradiction by combining the two descriptions to provide a single, coherent summary.', '"TCHP REGIMEN":Here is a comprehensive summary of the data:\n\nThe "TCHP REGIMEN" is a chemotherapy regimen used to treat breast cancer. Specifically, it is a combination therapy that includes trastuzumab and pertuzumab, two targeted therapies that work together to combat the disease.']}
11:52:42,956 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"ZAKS T":Here is a comprehensive summary of the data:\n\nZaks T is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.', '"DESILVIO M":Here is a comprehensive summary of the data:\n\nDeSilvio M is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.', '"SALAZAR V":Here is a comprehensive summary of the data:\n\nSalazar V is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.', '"SPECTOR N":Here is a comprehensive summary of the data:\n\nSPECTOR N is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.', '"G5":"G5 is a study evaluating the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer."', '"ALVAREZ RH":Here is a comprehensive summary of the data:\n\nALVAREZ RH is an author of research papers on inflammatory breast cancer. Specifically, Alvarez RH is an author of a study on the limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients.', '"ENSOR J":"Ensor J is an author of a study on limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients."', '"HUONG TLP":"Huong TLP is an author of a study on limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients."', '"JOHNSTON S":"Johnston S is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"TRUDEAU M":"Trudeau M is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"KAUFMAN B":"Kaufman B is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"BLACKWELL K":"Blackwell K is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"LORUSSO P":"LoRusso P is an author of a study on predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."', '"J CLIN ONCOL CONF":"J Clin Oncol Conf is a conference that presented a study on limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients."', '"PHASE II STUDY":"Phase II study is a type of clinical trial that evaluated the efficacy and safety of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients.""Phase II study is a type of clinical trial that evaluated the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer."', '"PREDICTIVE BIOMARKER PROFILES":"Predictive biomarker profiles refer to the identification of biomarkers that can predict response to treatment targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer patients."']}
11:53:04,980 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"HER2+ EARLY BREAST CANCER":"HER2+ early breast cancer is a condition being researched and treated in the NeoALTTO trial."', '"PHER2":"pHER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHER3":"pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER2":"phosphorylated HER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER3":"phosphorylated HER3 is a concept or marker that is associated with response to lapatinib treatment."', '"CO-EXPRESSION":"co-expression of phosphorylated HER2 and pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"DOSE REDUCTION":"dose reduction is an event that may occur due to toxicity of treatment."', '"DISCONTINUATION OF TREATMENT":"discontinuation of treatment is an event that may occur due to toxicity of treatment."', '"TOXICITY":"toxicity is a concept or marker that is associated with the side effects of treatment."', '"RESPONSE RATE":Here is a comprehensive summary of the data:\n\nThe "RESPONSE RATE" refers to the percentage of participants or patients who respond to a treatment. It is a concept or marker that is associated with the effectiveness of treatment. In other words, response rate measures the proportion of individuals who exhibit a positive outcome or improvement in response to a particular treatment or intervention.', '"PREDICTIVE MARKER":"predictive marker is a concept or marker that is associated with the likelihood of response to treatment."', '"PCR RATE":Here is a comprehensive summary of the data:\n\nThe "PCR Rate" is a concept or marker that measures the effectiveness of treatment, specifically in the context of breast cancer and inflammatory breast cancer (IBC). It is an endpoint in clinical trials for IBC and refers to the percentage of patients who achieve a pathologic complete response (pCR) to treatment. In other words, the pCR rate is the rate of patients who achieve a complete response to treatment, as determined by a pathologic examination of the breast tissue. This rate is used to assess the effectiveness of treatments for breast cancer and IBC, providing valuable information for healthcare professionals and researchers.', '"EARLY BREAST CANCER":"early breast cancer is an event or condition being researched and treated."', '"T-DM1":Here is a comprehensive summary of the data:\n\n"T-DM1" is a medication used in the treatment of breast cancer, specifically in the treatment of HER2+ breast cancer. It is a type of antibody-drug conjugate, which is a targeted therapy that combines an antibody with a chemotherapy drug to deliver the treatment directly to the cancer cells. T-DM1 is used to treat HER2+ breast cancer, including HER2+ inflammatory breast cancer (IBC) cases without a pathologic complete response (pCR).', '"KRISTINE TRIAL":Here is a comprehensive summary of the data:\n\nThe KRISTINE trial is a randomized phase 3 trial that evaluated the efficacy of neoadjuvant treatment with T-DM1 plus pertuzumab in patients with HER2+ breast cancer. Specifically, the trial aimed to assess the effectiveness of this combination therapy in treating HER2+ breast cancer.\n\nNote: I resolved the contradiction by combining the two descriptions to provide a single, coherent summary.', '"TCHP REGIMEN":Here is a comprehensive summary of the data:\n\nThe "TCHP REGIMEN" is a chemotherapy regimen used to treat breast cancer. Specifically, it is a combination therapy that includes trastuzumab and pertuzumab, two targeted therapies that work together to combat the disease.']}
11:53:04,981 datashaper.workflow.workflow ERROR Error executing verb "text_embed" in create_final_entities: Connection error.
Traceback (most recent call last):
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpx\_transports\default.py", line 69, in map_httpcore_exceptions
    yield
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpx\_transports\default.py", line 373, in handle_async_request
    resp = await self._pool.handle_async_request(req)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpcore\_async\connection_pool.py", line 216, in handle_async_request
    raise exc from None
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpcore\_async\connection_pool.py", line 196, in handle_async_request
    response = await connection.handle_async_request(
               ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpcore\_async\connection.py", line 99, in handle_async_request
    raise exc
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpcore\_async\connection.py", line 76, in handle_async_request
    stream = await self._connect(request)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpcore\_async\connection.py", line 122, in _connect
    stream = await self._network_backend.connect_tcp(**kwargs)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpcore\_backends\auto.py", line 30, in connect_tcp
    return await self._backend.connect_tcp(
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpcore\_backends\anyio.py", line 114, in connect_tcp
    with map_exceptions(exc_map):
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\contextlib.py", line 155, in __exit__
    self.gen.throw(typ, value, traceback)
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpcore\_exceptions.py", line 14, in map_exceptions
    raise to_exc(exc) from exc
httpcore.ConnectError: All connection attempts failed

The above exception was the direct cause of the following exception:

Traceback (most recent call last):
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\_base_client.py", line 1558, in _request
    response = await self._client.send(
               ^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpx\_client.py", line 1661, in send
    response = await self._send_handling_auth(
               ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpx\_client.py", line 1689, in _send_handling_auth
    response = await self._send_handling_redirects(
               ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpx\_client.py", line 1726, in _send_handling_redirects
    response = await self._send_single_request(request)
               ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpx\_client.py", line 1763, in _send_single_request
    response = await transport.handle_async_request(request)
               ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpx\_transports\default.py", line 372, in handle_async_request
    with map_httpcore_exceptions():
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\contextlib.py", line 155, in __exit__
    self.gen.throw(typ, value, traceback)
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpx\_transports\default.py", line 86, in map_httpcore_exceptions
    raise mapped_exc(message) from exc
httpx.ConnectError: All connection attempts failed

The above exception was the direct cause of the following exception:

Traceback (most recent call last):
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\datashaper\workflow\workflow.py", line 415, in _execute_verb
    result = await result
             ^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\index\verbs\text\embed\text_embed.py", line 105, in text_embed
    return await _text_embed_in_memory(
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\index\verbs\text\embed\text_embed.py", line 130, in _text_embed_in_memory
    result = await strategy_exec(texts, callbacks, cache, strategy_args)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\index\verbs\text\embed\strategies\openai.py", line 61, in run
    embeddings = await _execute(llm, text_batches, ticker, semaphore)
                 ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\index\verbs\text\embed\strategies\openai.py", line 105, in _execute
    results = await asyncio.gather(*futures)
              ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\asyncio\tasks.py", line 339, in __wakeup
    future.result()
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\asyncio\tasks.py", line 267, in __step
    result = coro.send(None)
             ^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\index\verbs\text\embed\strategies\openai.py", line 99, in embed
    chunk_embeddings = await llm(chunk)
                       ^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\caching_llm.py", line 104, in __call__
    result = await self._delegate(input, **kwargs)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 177, in __call__
    result, start = await execute_with_retry()
                    ^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 159, in execute_with_retry
    async for attempt in retryer:
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\tenacity\_asyncio.py", line 71, in __anext__
    do = self.iter(retry_state=self._retry_state)
         ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\tenacity\__init__.py", line 325, in iter
    raise retry_exc.reraise()
          ^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\tenacity\__init__.py", line 158, in reraise
    raise self.last_attempt.result()
          ^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\concurrent\futures\_base.py", line 449, in result
    return self.__get_result()
           ^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\concurrent\futures\_base.py", line 401, in __get_result
    raise self._exception
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 165, in execute_with_retry
    return await do_attempt(), start
           ^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 147, in do_attempt
    return await self._delegate(input, **kwargs)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\base_llm.py", line 49, in __call__
    return await self._invoke(input, **kwargs)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\base_llm.py", line 53, in _invoke
    output = await self._execute_llm(input, **kwargs)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\openai_embeddings_llm.py", line 36, in _execute_llm
    embedding = await self.client.embeddings.create(
                ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\resources\embeddings.py", line 215, in create
    return await self._post(
           ^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\_base_client.py", line 1826, in post
    return await self.request(cast_to, opts, stream=stream, stream_cls=stream_cls)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\_base_client.py", line 1519, in request
    return await self._request(
           ^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\_base_client.py", line 1592, in _request
    raise APIConnectionError(request=request) from err
openai.APIConnectionError: Connection error.
11:53:05,80 graphrag.index.reporting.file_workflow_callbacks INFO Error executing verb "text_embed" in create_final_entities: Connection error. details=None
11:53:05,125 graphrag.index.run ERROR error running workflow create_final_entities
Traceback (most recent call last):
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpx\_transports\default.py", line 69, in map_httpcore_exceptions
    yield
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpx\_transports\default.py", line 373, in handle_async_request
    resp = await self._pool.handle_async_request(req)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpcore\_async\connection_pool.py", line 216, in handle_async_request
    raise exc from None
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpcore\_async\connection_pool.py", line 196, in handle_async_request
    response = await connection.handle_async_request(
               ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpcore\_async\connection.py", line 99, in handle_async_request
    raise exc
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpcore\_async\connection.py", line 76, in handle_async_request
    stream = await self._connect(request)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpcore\_async\connection.py", line 122, in _connect
    stream = await self._network_backend.connect_tcp(**kwargs)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpcore\_backends\auto.py", line 30, in connect_tcp
    return await self._backend.connect_tcp(
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpcore\_backends\anyio.py", line 114, in connect_tcp
    with map_exceptions(exc_map):
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\contextlib.py", line 155, in __exit__
    self.gen.throw(typ, value, traceback)
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpcore\_exceptions.py", line 14, in map_exceptions
    raise to_exc(exc) from exc
httpcore.ConnectError: All connection attempts failed

The above exception was the direct cause of the following exception:

Traceback (most recent call last):
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\_base_client.py", line 1558, in _request
    response = await self._client.send(
               ^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpx\_client.py", line 1661, in send
    response = await self._send_handling_auth(
               ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpx\_client.py", line 1689, in _send_handling_auth
    response = await self._send_handling_redirects(
               ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpx\_client.py", line 1726, in _send_handling_redirects
    response = await self._send_single_request(request)
               ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpx\_client.py", line 1763, in _send_single_request
    response = await transport.handle_async_request(request)
               ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpx\_transports\default.py", line 372, in handle_async_request
    with map_httpcore_exceptions():
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\contextlib.py", line 155, in __exit__
    self.gen.throw(typ, value, traceback)
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpx\_transports\default.py", line 86, in map_httpcore_exceptions
    raise mapped_exc(message) from exc
httpx.ConnectError: All connection attempts failed

The above exception was the direct cause of the following exception:

Traceback (most recent call last):
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\index\run.py", line 323, in run_pipeline
    result = await workflow.run(context, callbacks)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\datashaper\workflow\workflow.py", line 369, in run
    timing = await self._execute_verb(node, context, callbacks)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\datashaper\workflow\workflow.py", line 415, in _execute_verb
    result = await result
             ^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\index\verbs\text\embed\text_embed.py", line 105, in text_embed
    return await _text_embed_in_memory(
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\index\verbs\text\embed\text_embed.py", line 130, in _text_embed_in_memory
    result = await strategy_exec(texts, callbacks, cache, strategy_args)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\index\verbs\text\embed\strategies\openai.py", line 61, in run
    embeddings = await _execute(llm, text_batches, ticker, semaphore)
                 ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\index\verbs\text\embed\strategies\openai.py", line 105, in _execute
    results = await asyncio.gather(*futures)
              ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\asyncio\tasks.py", line 339, in __wakeup
    future.result()
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\asyncio\tasks.py", line 267, in __step
    result = coro.send(None)
             ^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\index\verbs\text\embed\strategies\openai.py", line 99, in embed
    chunk_embeddings = await llm(chunk)
                       ^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\caching_llm.py", line 104, in __call__
    result = await self._delegate(input, **kwargs)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 177, in __call__
    result, start = await execute_with_retry()
                    ^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 159, in execute_with_retry
    async for attempt in retryer:
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\tenacity\_asyncio.py", line 71, in __anext__
    do = self.iter(retry_state=self._retry_state)
         ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\tenacity\__init__.py", line 325, in iter
    raise retry_exc.reraise()
          ^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\tenacity\__init__.py", line 158, in reraise
    raise self.last_attempt.result()
          ^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\concurrent\futures\_base.py", line 449, in result
    return self.__get_result()
           ^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\concurrent\futures\_base.py", line 401, in __get_result
    raise self._exception
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 165, in execute_with_retry
    return await do_attempt(), start
           ^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 147, in do_attempt
    return await self._delegate(input, **kwargs)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\base_llm.py", line 49, in __call__
    return await self._invoke(input, **kwargs)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\base_llm.py", line 53, in _invoke
    output = await self._execute_llm(input, **kwargs)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\openai_embeddings_llm.py", line 36, in _execute_llm
    embedding = await self.client.embeddings.create(
                ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\resources\embeddings.py", line 215, in create
    return await self._post(
           ^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\_base_client.py", line 1826, in post
    return await self.request(cast_to, opts, stream=stream, stream_cls=stream_cls)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\_base_client.py", line 1519, in request
    return await self._request(
           ^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\_base_client.py", line 1592, in _request
    raise APIConnectionError(request=request) from err
openai.APIConnectionError: Connection error.
11:53:05,178 graphrag.index.reporting.file_workflow_callbacks INFO Error running pipeline! details=None
